Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

NCT02768805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

900

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions

BIOLOGICAL: 15 µg/strain of Quadrivalent VLP Vaccine
BIOLOGICAL: 30 µg/strain of Quadrivalent VLP Vaccine
BIOLOGICAL: 15 µg/strain of the licensed quadrivalent vaccine

Sponsor

Medicago